AGTC Expands its Clinical and Regulatory Expertise with Appointment of Jeffrey Chulay M.D. as Vice President of Chief Medical Officer
July 9 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that Dr. Jeffrey Chulay has joined the company as Chief Medical Officer and Vice President of Regulatory Affairs.
Dr. Chulay brings broad medical and regulatory expertise to the Company. He joins AGTC from AlphaVax, where he worked as Senior Vice President of Medical Affairs and Chief Medical Officer. Prior to joining AlphaVax, Dr. Chulay was at GlaxoSmithKline, where he worked as Principal Clinical Program Head of clinical research in HIV and Opportunistic Infections. Before joining GSK (then Burroughs Wellcome), Dr. Chulay served as Chief of the Department of Immunology at Walter Reed Army Institute of Research (WRAIR) and Chief of the Virology Division at the U.S. Army Research Institute of Infectious Disease (USAMRIID).
Dr. Chulay earned a medical degree from Northwestern University Medical School and a degree in tropical medicine and hygiene from the London School of Hygiene and Tropical Medicine. He served his residency at Cleveland Metropolitan General Hospital and was a fellow in Infectious Disease at WRAIR. He is a reviewer for several leading journals on infectious disease.
Sue Washer, CEO of AGTC, said: “We are very pleased that Jeff has joined our team. His experience with clinical development programs and viral vectors are key additions to our management team, which now has the complete set of capabilities required to meet our ambitious growth plans.”